A New Perspective on Stem Cell Therapy for Diabetic Erectile Dysfunction

Diabetic erectile dysfunction (DMED) remains one of the most prevalent and challenging complications of diabetes, affecting up to half of men with the disease [1]. Conventional therapies, including phosphodiesterase type 5 inhibitors, intracavernosal injections, and vacuum devices, often provide only transient symptomatic relief and fail to reverse the underlying pathophysiological damage. Diabetic men are frequently refractory to first-line pharmacological approaches such as PDE5 inhibitors, underscoring the urgent need for therapeutic strategies that target the neural, endothelial, and smooth muscle deterioration characteristic of DMED. This clinical scenario has propelled regenerative approaches into the spotlight, with stem cell-based therapies emerging as promising alternatives. However, despite encouraging preclinical data, significant knowledge gaps remain regarding the optimal stem cell type, delivery method, long-term efficacy, and translational safety. In this context, the recent study by Wiriyabanditkul et al. (2025) provides relevant new evidence by demonstrating that intracavernous injection of amniotic fluid-derived stem cells (AFSCs) improves erectile function and penile tissue integrity in a streptozotocin-induced model of type 1 diabetes. The authors reported restoration of neuronal, endothelial, and smooth muscle markers, along with a reduction in senescence-associated β-galactosidase activity. These results support a multifaceted mechanism of action and reinforce the therapeutic potential of AFSCs in the setting of DMED [2]. The most compelling contribution of the study lies in its demonstration of erectile functional recovery. Intracavernosal pressure relative to mean arterial pressure (ICP/MAP) was significantly improved in diabetic rats treated with AFSCs compared with untreated diabetic controls. Although erectile responses in treated animals remained below those of healthy controls, the improvement highlights the therapeutic potential of AFSCs in counteracting the neurovascular damage associated with chronic hyperglycemia. The histological and cellular data provide mechanistic insight into the functional improvement. AFSC treatment increased TUBB3 and α-SMA expression, indicating enhanced neuronal integrity and smooth muscle preservation, while RECA staining showed partial endothelial recovery. A decrease in β-galactosidase activity also pointed to reduced cellular senescence [2]. Unlike other regenerative approaches such as PRP or ADSCs, which often show limited or single-pathway effects [3, 4], AFSCs appear to act on multiple targets within the erectile tissue, offering a broader reparative profile. Beyond the specific results, this study stands out for addressing an important gap in the field. While adipose- and bone marrow-derived stem cells have been extensively tested in models of erectile dysfunction [5], AFSCs have mostly been evaluated in the context of bilateral cavernous nerve crush (BCNC) injury [6] or bladder dysfunction [7]. Their use in diabetic ED models remains rare. By showing both functional improvement and histological repair, Wiriyabanditkul et al. help broaden the potential applications of AFSCs and bring a new regenerative option to a condition that is often difficult to treat. One of the strengths of this study is its solid experimental design, which uses a well-established DMED model and integrates functional, histological, and cellular analyses. The agreement between ICP measurements and tissue-level changes gives more weight to the results. The choice of AFSCs also adds clinical relevance, as these cells are accessible, less immunogenic, and raise fewer ethical concerns than embryonic stem cells. Despite these strengths, some important questions remain. The relatively short follow-up period does not yet allow firm conclusions about the long-term durability of the therapeutic effects, leaving open whether the observed improvements are sustained or represent transient changes. In addition, although the selected AFSC dose (1 × 10⁶ cells per rat) follows previous preclinical studies, the study was not specifically designed to explore dose–response relationships. Providing a rationale for dose selection or examining alternative dosing regimens in future work could help refine the therapeutic window and better inform clinical translation. Preclinical evidence indicates that stem cell-based approaches may achieve greater efficacy when combined with adjunctive strategies. In a rat model of post-prostatectomy erectile dysfunction, human adipose-derived stem cells applied to the cavernous nerve in combination with low-energy shockwave therapy to the corpus cavernosum produced superior recovery of erectile function compared with either treatment alone [8]. Similarly, in a diabetic model, the antioxidant probucol enhanced the therapeutic efficiency of mesenchymal stem cells by prolonging their survival through activation of the Nrf2 pathway [9]. These findings highlight that optimizing the microenvironment or integrating supportive modalities can potentiate stem cell-mediated repair. Whether AFSCs might also benefit from such combinatorial strategies remains an open but promising area for future research. Another consideration is the absence of direct assessment of the nitric oxide–soluble guanylate cyclase–cGMP pathway, the central mediator of cavernosal smooth muscle relaxation. The functional and histological improvements observed in this study indirectly suggest recovery of this signaling cascade, but molecular analyses of NOS isoforms, cGMP production, or related downstream targets were not included. Because the NO–cGMP axis is fundamental for erectile physiology and known to be impaired in diabetic states, incorporating these endpoints in future work could help clarify whether AFSCs restore erectile function mainly through this pathway or via complementary mechanisms. Another relevant aspect is the hypercontractility of the corpus cavernosum, largely driven by increased α1-adrenergic receptor activity, which is a well-recognized feature of the streptozotocin model [10]. This alteration contributes to erectile dysfunction by shifting the balance toward smooth muscle contraction. The study was not specifically designed to evaluate whether AFSC therapy influences this component of the pathophysiology. Incorporating adrenergic functional assays in future studies could provide a more comprehensive understanding of how AFSCs act on the mechanisms underlying DMED. The study utilized streptozotocin to induce diabetes in rats, a well-established approach that closely models type 1 diabetes through selective pancreatic β-cell destruction and persistent hyperglycemia. While the authors discussed DMED in general terms, it is worth noting that type 2 diabetes represents the predominant clinical scenario in men with ED, characterized by additional mechanisms such as obesity, insulin resistance, chronic inflammation, and vascular dysfunction. Evaluating AFSC therapy in type 2 diabetes models, whether diet-induced or genetic, would therefore provide important insight into its broader translational relevance. In summary, Wiriyabanditkul et al. provide important evidence supporting the potential of AFSCs in DMED. The combination of functional recovery with histological repair strengthens the rationale for further investigation. Although questions remain regarding durability, optimal dosing, and applicability to type 2 diabetes, this study broadens the scope of regenerative approaches and establishes a useful basis for future translational work. Study conception and design: Fábio Henrique Silva. Drafting of the article: Fábio Henrique Silva. Critical revision of the article for important intellectual content: Fábio Henrique Silva. Final approval of the version to be published: Fábio Henrique Silva. The author declares no conflicts of interest. No new data were generated in this study.